Status:
RECRUITING
Gut Microbiota in the Progression of Alpha-synucleinopathies
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
REM Sleep Behavior Disorder
Eligibility:
All Genders
Brief Summary
The aim of this study is to correlate baseline gut microbiota features and the progression of neurodegeneration in the established cohort of patients with early Parkinson's disease.
Detailed Description
Alpha-synucleinopathy is a major group of neurodegenerative diseases that include Parkinson's disease and Dementia of Lewy bodies. They are known to have a long preclinical development, and prodromal ...
Eligibility Criteria
Inclusion
- recruit from the subjects who completed the baseline study
Exclusion
- The use of probiotics or antibiotics within three months prior to sample collection;
- Pre-existing gastrointestinal diseases, such as inflammatory bowel disease.
- Not capable of giving informed consent for participation of the study.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
490 Patients enrolled
Trial Details
Trial ID
NCT05353868
Start Date
February 1 2022
End Date
June 30 2024
Last Update
April 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong